Current Quality-of-Life Aspects in Patients with Classical Ph-Negative Myeloproliferative Neoplasms in the Russian Federation: Overview of the Outcomes of the National Observational Program MPN-QoL-2020
Authors: Ionova T.I. , Andreevskaya E.A. , Babich E.N. , Bulieva N.B. , Vinogradova O.Yu. , Volodicheva E.M. , Voloshin S.V. , Glonina N.N. , Dubov S.K. , Esef'eva N.B. , Zaritskey A.Yu. , Ivanova M.O. , Klitochenko T.Yu. , Kopylova A.V. , Kulagin A.D. , Kuchma G.B. , Li O.Yu. , Lomaia E.G. , Melikyan A.L. , Melnichenko V.Ya. , Menshakova S.N. , Minaeva N.V. , Mitina T.A. , Morozova E.V. , Nikitina Tatyana Pavlovna , Ochirova O.E. , Polyakov A.S. , Pospelova T.I. , Proidakov A.V. , Rukavitsyn O.A. , Safuanova G.Sh. , Subortseva I.N. , Fominykh M.S. , Frolova M.V. , Shelekhova T.V. , Sherstnev D.G. , Shneidei T.V. , Shuvaev V.A. , Abdulkhalikova Z.K. , Anchukova L.V. , Apanaskevich I.A. , Arnautova A.N. , Barabanshchikova M.V. , Berlina N.V. , Bityukov A.P. , Gilyazitdinova E.A. , Gilmanshina V.I. , Egorova E.K. , Efremova E.V. , Zhalsanova E.B. , Kabanova E.N. , Kalashnikova O.B. , Kersilova A.E. , Kolosheinova T.I. , Kondratovskii P.M. , Koroleva E.V. , Kotelnikova A.N. , Lazareva N.A. , Lazorko N.S. , Lyyurova E.V. , Lyamkina A.S. , Maslova Yu.N. , Mileeva E.S. , Mochkin N.E. , Nekhai E.K. , Noskov Ya.A. , Osipova E.S. , Pankrashkina M.M. , Potanina E.V. , Rudenko O.D. , Rozhenkova T.Yu. , Sbityakova E.I. , Siordiya N.T. , Talko A.V. , Usacheva E.I. , Chernykh Yu.B. , Chitanava T.V. , Shashkina K.S. , Shikhbabaeva D.I. , Yurovskaya K.S. , Zinina E.E. 
Published: April 2022

Background. The national observational program MPN-QoL-2020 was focused on quality of life (QoL) and symptoms in patients with classical Ph-negative myeloproliferative neoplasms (MPNs) in the Russian Federation, as well as on the perception of the disease and treatment from the patient's and physician's perspective. Aim. To evaluate QoL in patients with different MPNs using new standardized questionnaires, to assess the most common symptoms and their impact on QoL in patients with myelofibrosis (MF), polycythemia vera (PV) and essential throm-bocythemia (ET), and to characterize the perception of the disease and treatment concerns from patients' perspective and their treating physicians' perspective. Materials & Methods. In total 1100 patients with MPNs (MF: n = 355, PV: n = 408, and ET: n = 337; mean age 58 ± 14 years; 61 % women) and 100 hematologists (mean age 42 ± 12 years; 85 % women) from 37 medical centers in 8 Federal districts of the Russian Federation participated in the study. All the patients filled out symptom assessment tool (MPN10), QoL questionnaire for patients with hematological nancies (HM-PRO) and patient's survey checklist; physicians filled out physician's survey checklist and patient record for each patient included in the study. Results. For the first time in Russia in a representative population of MPN patients in the real-world setting, QoL and symptom profiles in patients with different MPNs were characterized and symptom impact on the daily living of MPN patients was identified. MPN patients exhibited QoL impairment: noticeable detriments in physical and emotional functioning, as well as in eating and drinking regimen were found, social functioning was less impaired. More than one third of MPN patients had significant QoL impairment. The vast majority of patients experienced fatigue: 92.6 % MF patients, 83.7 % PI patients, and 82 % ET patients. Symptom prevalence severity differed across different MPNs. Top disease-related symptoms to be resolved were identified from patient's and physician's perspective. Discrepancies in the attitudes of MPN patients and their treating physicians to various aspects regarding the disease and its treatment were found as well as issues needed to be improved in the patient-physician communication were identified. Conclusion. The results of national research program MPN-QoL-2020 allowed to identify the areas of QoL impairment and symptom burden in MPN patients in Russia, to verify areas of concern related to the disease and its treatment in patients with different MPNs, as well as to highlight the unmet needs in this patients' population in our country. The outcomes of the study may contribute to establishing recommendations for improving/maintaining QoL in patients with MPNs and to developing measures aimed to raise awareness of this patients' population about the disease and its treatment.